NTLA - Intellia Therapeutics - Stock & Dividends

Intellia Therapeutics Inc. is a pioneering genome editing company dedicated to developing curative therapeutics that transform lives. Their innovative approach focuses on harnessing the power of gene editing to treat a range of debilitating diseases.

The company's in vivo programs are making significant strides, with NTLA-2001 currently in Phase 1 clinical trial for the treatment of transthyretin amyloidosis, a rare and debilitating genetic disorder. Additionally, Intellia is advancing NTLA-2002 for the treatment of hereditary angioedema, a life-threatening condition characterized by recurring attacks of swelling. Furthermore, NTLA-3001 is being developed to treat alpha-1 antitrypsin deficiency associated lung disease, a genetic disorder that can lead to severe respiratory problems.

Beyond these programs, Intellia is also exploring treatments for hemophilia A and hemophilia B, as well as researching proprietary programs focused on developing engineered cell therapies to combat various cancers and autoimmune diseases. This includes leveraging cutting-edge technologies like the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system to develop novel treatments.

Intellia has established strategic partnerships with leading biotech companies, including Regeneron Pharmaceuticals, AvenCell Therapeutics, SparingVision, Kyverna Therapeutics, and ONK Therapeutics. These collaborations aim to co-develop and co-commercialize innovative products for the treatment of hemophilia, cancer, and autoimmune diseases.

Founded in 2014, Intellia Therapeutics is headquartered in Cambridge, Massachusetts, and is committed to pushing the boundaries of genome editing to deliver life-changing therapies. For more information, visit their website at https://www.intelliatx.com.